$5.21
0.132.56%
Last update: Nov 11, 12:54 PM
Kyverna Therapeutics Inc
KYTXNASDAQ
Kyverna Therapeutics fell 26.1% from $7.00 to $5.17, behind the S&P 500's +9.8%. Its worst day was Dec 17 (−32.5%), and its low came Nov 5 at $4.61.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.85 beat the $-0.96 estimate on $0.00 revenue.
−11.6% · S&P 500 −1.7%
Kyverna Therapeutics shares fell 32.5%, while the S&P 500 fell 1.1%.
Story events cover the past 12 months · Times ET
−32.5%, the year's worst day · S&P 500 −1.1%
EPS of $-0.80 beat the $-0.84 estimate on $0.00 revenue.
−2.9% · S&P 500 −1.7%
Kyverna Therapeutics closed at its highest level of the year, 60.7% above where the year started.
+13.3% · S&P 500 −0.2%
EPS of $-0.66 beat the $-0.73 estimate on $0.00 revenue.
+5.4% · S&P 500 +0.6%
EPS of $-0.63 beat the $-0.68 estimate on $0.00 revenue.
+0.4% · S&P 500 +0.3%
Where it ended: a close of $5.17 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.69).
Nothing in the past 12 months.
All KYTX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KYTX and SPY from Benzinga historical bars. Not investment advice.
